SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $750,841 | -6.4% | 27,234 | +2.0% | 0.01% | 0.0% |
| Q2 2023 | $802,211 | -19.1% | 26,687 | -2.5% | 0.01% | -28.6% |
| Q1 2023 | $991,361 | +1.9% | 27,363 | +0.3% | 0.01% | 0.0% |
| Q4 2022 | $972,864 | +5.7% | 27,274 | +0.4% | 0.01% | 0.0% |
| Q3 2022 | $920,000 | +18.4% | 27,173 | +1.1% | 0.01% | +40.0% |
| Q2 2022 | $777,000 | -15.5% | 26,877 | -5.5% | 0.01% | 0.0% |
| Q1 2022 | $920,000 | +4.5% | 28,451 | -5.7% | 0.01% | +25.0% |
| Q4 2021 | $880,000 | +5.9% | 30,180 | -3.1% | 0.00% | 0.0% |
| Q3 2021 | $831,000 | -16.3% | 31,151 | -3.4% | 0.00% | +33.3% |
| Q2 2021 | $993,000 | +15.6% | 32,245 | -1.8% | 0.00% | 0.0% |
| Q1 2021 | $859,000 | +2.8% | 32,830 | -1.2% | 0.00% | 0.0% |
| Q4 2020 | $836,000 | +17.9% | 33,214 | -2.4% | 0.00% | 0.0% |
| Q3 2020 | $709,000 | -14.4% | 34,033 | -2.4% | 0.00% | -25.0% |
| Q2 2020 | $828,000 | +34.4% | 34,863 | +1.9% | 0.00% | +33.3% |
| Q1 2020 | $616,000 | -27.7% | 34,221 | -4.7% | 0.00% | 0.0% |
| Q4 2019 | $852,000 | -16.0% | 35,907 | -2.7% | 0.00% | -25.0% |
| Q3 2019 | $1,014,000 | -17.9% | 36,906 | -1.1% | 0.00% | -20.0% |
| Q2 2019 | $1,235,000 | -5.7% | 37,321 | -0.2% | 0.01% | 0.0% |
| Q1 2019 | $1,310,000 | +2.7% | 37,393 | -2.6% | 0.01% | 0.0% |
| Q4 2018 | $1,275,000 | -34.8% | 38,391 | -1.2% | 0.01% | -16.7% |
| Q3 2018 | $1,956,000 | -14.1% | 38,848 | +2.1% | 0.01% | -25.0% |
| Q2 2018 | $2,278,000 | +61.1% | 38,064 | +23.3% | 0.01% | +60.0% |
| Q1 2018 | $1,414,000 | -8.5% | 30,877 | -20.3% | 0.01% | 0.0% |
| Q4 2017 | $1,545,000 | +1.8% | 38,761 | +2.2% | 0.01% | 0.0% |
| Q3 2017 | $1,517,000 | -1.8% | 37,920 | +5.8% | 0.01% | -16.7% |
| Q2 2017 | $1,545,000 | +70.9% | 35,850 | +24.1% | 0.01% | +100.0% |
| Q1 2017 | $904,000 | +3.0% | 28,891 | -17.0% | 0.00% | 0.0% |
| Q4 2016 | $878,000 | -99.9% | 34,792 | -1.5% | 0.00% | 0.0% |
| Q3 2016 | $873,513,000 | +30.6% | 35,322 | +7.6% | 0.00% | 0.0% |
| Q2 2016 | $668,890,000 | +51.7% | 32,837 | +13.7% | 0.00% | +50.0% |
| Q1 2016 | $441,000,000 | +18.5% | 28,892 | +4.2% | 0.00% | 0.0% |
| Q4 2015 | $372,000,000 | +104394.4% | 27,719 | +9.1% | 0.00% | 0.0% |
| Q3 2015 | $356,000 | -99.9% | 25,411 | +3.2% | 0.00% | 0.0% |
| Q2 2015 | $418,133,000 | +87.8% | 24,625 | +33.7% | 0.00% | +100.0% |
| Q1 2015 | $222,613,000 | +45.7% | 18,413 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $152,828,000 | -8.1% | 18,413 | -3.8% | 0.00% | 0.0% |
| Q3 2014 | $166,344,000 | -20.7% | 19,142 | -0.1% | 0.00% | 0.0% |
| Q2 2014 | $209,758,000 | +112.2% | 19,156 | +73.2% | 0.00% | – |
| Q1 2014 | $98,859,000 | +21.5% | 11,058 | +2.5% | 0.00% | – |
| Q4 2013 | $81,372,000 | +11.2% | 10,792 | +8.1% | 0.00% | – |
| Q3 2013 | $73,153,000 | +284.6% | 9,980 | +237.4% | 0.00% | – |
| Q2 2013 | $19,020,000 | – | 2,958 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |